Publications by authors named "J Mueller-Brand"

Claim this Profile
9
90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas.
Karine Gerster-Gilliéron, Flavio Forrer, Helmut Maecke, Jan Mueller-Brand, Adrian Merlo

J Nucl Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GEPNETs update: Radionuclide therapy in neuroendocrine tumors.
Wouter A van der Zwan, Lisa Bodei, Jan Mueller-Brand, Wouter W de Herder, Larry K Kvols

Eur J Endocrinol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas.
Flavio Forrer, Catharina Oechslin-Oberholzer, Benedetta Campana, Richard Herrmann, Helmut R Maecke, Jan Mueller-Brand

J Nucl Med· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.
L Bodei, J Mueller-Brand, R P Baum, M E Pavel, D Hörsch

Eur J Nucl Med Mol Imaging· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab.
F Forrer, C Oechslin-Oberholzer, B Campana, H Maecke, J Mueller-Brand

Q J Nucl Med Mol Imaging· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis